Breaking News, Collaborations & Alliances

AbbVie and Gedeon Richter Enter Co-Development and License Agreement

Will research, develop and commercialize novel dopamine receptor modulators for the potential treatment of neuropsychiatric diseases.

Author Image

By: Charlie Sternberg

Associate Editor

AbbVie and Gedeon Richter Plc. have entered a new co-development and license agreement to research, develop and commercialize novel dopamine receptor modulators for the potential treatment of neuropsychiatric diseases.   The collaboration is based on the results of preclinical research carried out by Richter and includes several new chemical entities selected for development. AbbVie and Richter have collaborated for 15 years on Central Nervous System (CNS) projects, including globally launched...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters